Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone.
Satoh
Noriko
N
Shimatsu
Akira
A
Himeno
Akihiro
A
Sasaki
Yousuke
Y
Yamakage
Hajime
H
Yamada
Kazunori
K
Suganami
Takayoshi
T
Ogawa
Yoshihiro
Y
D015214:Antigens, Differentiation, Myelomonocytic / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology*; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000276:immunology*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015214:Antigens, Differentiation, Myelomonocytic; D007004:Hypoglycemic Agents; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000077205:Pioglitazone